Immunovant (IMVT) Stock News and Forecast for Dec. 14, 2025: $550M Financing Closes, Roivant Buys $350M, Analysts Update Targets
Immunovant, Inc. (NASDAQ: IMVT) stock is closing out the week in focus after the company completed a major equity raise designed to bolster funding for its autoimmune pipeline—while its controlling shareholder, Roivant Sciences, stepped in as the largest buyer. As